The current role of model-based drug development

Expert Opinion on Drug Discovery

Volumn 5, Issue 4, 2010, Pages 311-321

  Suryawanshi, Satyendra ^a   Zhang, Liping ^b   Pfister, Marc ^b   Meibohm, Bernd ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b BRISTOL MYERS SQUIBB RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Drug development; Modeling; Pharmacodynamics; Pharmacokinetics; Simulation

Indexed keywords

DRUG;

DECISION MAKING; DRUG DESIGN; MOLECULAR MODEL; PRIORITY JOURNAL; PRODUCTIVITY; REVIEW; SIMULATION;

EID: 77950295526     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441003713470     Document Type: Review

References (49)

1. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev 2004;3(8):711-715
2. Frantz S. Pipeline problems are increasing the urge to merge. Nat Rev 2006;5(12):977-979
3. European Medicines Agency. The European Medicines Agency Road Map to 2010: preparing the ground for the future. London; 2005
4. US Food and Drug Administration. Innovation/stagnation: challenge and opportunity on the critical path to new medical products. Rockville, MD; 2004
5. Csajka C, Verotta D. Pharmacokinetic-pharmacodynamic modelling: history and perspectives. J Pharmacokinet Pharmacodyn 2006;33(3):227-229
6. Breimer DD, Danhof M. Relevance of the application of pharmacokinetic-pharmacodynamic modelling concepts in drug development. The "wooden shoe" paradigm. Clin Pharmacokinet 1997;32(4):259-267
7. Meibohm B, Derendorf H. Pharmacokinetic/pharmacodynamic studies in drug product development. J Pharm Sci 2002;91(1):18-31
8. Peck CC, Barr BW, Benet LZ, et al. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. Pharm Res 1992;9(6):826-833
9. Sheiner LB. Learning versus confirming in clinical drug development. Clin Pharmacol Ther 1997;61(3):275-291
10. Krishna R. Quantitative clinical pharmacology: making paradigm shifts a reality. J Clin Pharmacol 2006;46(9):966-967
11. Perelson AS. Viral kinetics and mathematical models. Am J Med 1999;107(6B):49S-52S
12. Pfister M, Martin NE, Haskell LP, Barrett JS. Optimizing dose selection with modeling and simulation: application to the vasopeptidase inhibitor M100240. J Clin Pharmacol 2004;44(6):621-631
13. Garcia-Mora B, Santamaria C, Rubio G, Pontones J. Modeling the recurrence-progression process in bladder carcinoma. Comput Math Appl 2008;53:619-630
14. Holford NH, Kimko HC, Monteleone JP, Peck CC. Simulation of clinical trials. Ann Rev Pharmacol Toxicol 2000;40:209-234
15. Eriksen S, Keller LR. A multiattribute-utility-function approach to weighing the risks and benefits of pharmaceutical agents. Med Decis Making 1993;13(2):118-125
16. Zhang L, Sinha V, Forgue ST, et al. Model-based drug development: the road to quantitative pharmacology. J Pharmacokinet Pharmacodyn 2006;33(3):369-393
17. Bhattaram VA, Booth BP, Ramchandani RP, et al. Impact of pharmacometrics on drug approval and labeling decisions: a survey of 42 new drug applications. AAPS J 2005;7(3):E503-12
18. Zhang L, Pfister M, Meibohm B. Concepts and challenges in quantitative pharmacology and model-based drug development. AAPS J 2008;10(4):552-559
19. Gobburu JV, Lesko LJ. Quantitative disease, drug, and trial models. Ann Rev Pharmacol Toxicol 2009;49:291-301
20. Lalonde RL, Kowalski KG, Hutmacher MM, et al. Model-based drug development. Clin Pharmacol Ther 2007;82(1):21-32
21. Miller R, Ewy W, Corrigan BW, et al. How modeling and simulation have enhanced decision making in new drug development. J Pharmacokinet Pharmacodyn 2005;32(2):185-197
22. Grasela TH, Fiedler-Kelly J, Walawander CA, et al. Challenges in the transition to model-based development. AAPS J 2005;7(2):488-495
23. Gabrielsson J, Dolgos H, Gillberg PG, et al. Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: strategic considerations. Drug Discov Today 2009;14(7-8):358-372
24. Bhattaram VA, Siddiqui O, Kapcala LP, Gobburu JV. Endpoints and analyses to discern disease-modifying drug effects in early Parkinson's disease. AAPS J 2009;11(3):456-464
25. Krishna R, Schaefer HG, Bjerrum OJ. Effective integration of systems biology, biomarkers, biosimulation and modelling in streamlining drug development. Eur J Pharm Sci 2007;31(1):62-67
26. Venitz J. Using exposure-response and biomarkers to streamline early drug development. Ernst Schering Res Found Workshop 2007;59(1):47-63
27. Bhattaram VA, Bonapace C, Chilukuri DM, et al. Impact of pharmacometric reviews on new drug approval and labeling decisions--a survey of 31 new drug applications submitted between 2005 and 2006. Clin Pharmacol Ther 2007;81(2):213-221
28. Levy G. Mechanism-based pharmacodynamic modeling. Clin Pharmacol Ther 1994;56(4):356-358
29. Sheiner LB, Steimer JL. Pharmacokinetic/pharmacodynamic modeling in drug development. Ann Rev Pharmacol Toxicol 2000;40:67-95
30. Bies R, Ko HC, Gobburu J, et al. Effective incorporation of preclinical information into the decision making process for new drug development: an anonymous case study. Clin Pharmacol Ther 2000;67(2):107
31. Chien JY, Friedrich S, Heathman MA, et al. Pharmacokinetics/ pharmacodynamics and the stages of drug development: role of modeling and simulation. AAPS J 2005;7(3):544-559
32. Putnam WS, Li J, Haggstrom J, et al. Use of quantitative pharmacology in the development of HAE1, a high-affinity anti-IgE monoclonal antibody. AAPS J 2008;10(2):425-430
33. Chan PL, Holford NH. Drug treatment effects on disease progression. Ann Rev Pharmacol Toxicol 2001;41:625-659
34. Gobburu J. Disease models. Clin Adv Hematol Oncol 2008;6(4):241-242
35. Ploeger BA, Holford NH. Washout and delayed start designs for identifying disease modifying effects in slowly progressive diseases using disease progression analysis. Pharm Stat 2009;8(3):225-238
36. Gupta P, Friberg LE, Karlsson MO, et al. A semi-mechanistic model of CP-690,550-induced reduction in neutrophil counts in patients with rheumatoid arthritis. J Clin Pharmacol 2009. [Epub ahead of print]
37. Hale MD GW, Gupta SK, Tuk B, Holford NH. Clinical trial simulation: streamlining your drug development process. Appl Clin Trials 1996;5:35-40
38. Jumbe N, Yao B, Rovetti R, et al. Clinical trial simulation of a 200-microg fixed dose of darbepoetin alfa in chemotherapy-induced anemia. Oncology (Williston Park) 2002;16(10 Suppl 11):37-44
39. Thames WA, Smith SL, Scheifele AC, et al. Evaluation of the US Oncology Network's recommended guidelines for therapeutic substitution with darbepoetin alfa 200 microg every 2 weeks in both naive patients and patients switched from epoetin alfa. Pharmacotherapy 2004;24(3):313-323
40. Lockwood P, Ewy W, Hermann D, Holford N. Application of clinical trial simulation to compare proof-of-concept study designs for drugs with a slow onset of effect; an example in Alzheimer's disease. Pharm Res 2006;23(9):2050-2059
41. Poland B, Wada R. Combining drug-disease and economic modelling to inform drug development decisions. Drug Discov Today 2001;6(22):1165-1170
42. Khan AA, Perlstein I, Krishna R. The use of clinical utility assessments in early clinical development. AAPS J 2009;11(1):33-38
43. Zhang L. Dykstra K, Krishnaswami S. Communicating in a model-based drug development paradigm. AAPS Workshop 'Quantitative pharmacology: a roadmap to model-based drug development'; November 10 2007; San Diego, CA, USA
44. Gobburu JV, Marroum PJ. Utilisation of pharmacokinetic-pharmacodynamic modelling and simulation in regulatory decision-making. Clin Pharmacokinet 2001;40(12):883-892
45. Wang Y, Bhattaram AV, Jadhav PR, et al. Leveraging prior quantitative knowledge to guide drug development decisions and regulatory science recommendations: impact of FDA pharmacometrics during 2004-2006. J Clinical Pharmacol 2008;48(2):146-156
46. Lesko LJ. Paving the critical path: how can clinical pharmacology help achieve the vision? Clin Pharmacol Ther 2007;81(2):170-177
47. Jadhav PR, Zhang J, Gobburu JV. Leveraging prior quantitative knowledge in guiding pediatric drug development: a case study. Pharm Stat 2009;8(3):216-224
48. US Food and Drug Administration. Exposure response relationships: guidance for industry. Rockville, MD; 2003
49. Li F, Nandy P, Chien S, et al. Pharmacometrics-based dose selection of levofloxacin as a treatment for postexposure inhalational anthrax in children. Antimicrob Agents Chemother 2010;54(1):375-379